Chip Moebus, the new Vice President of Reimbursement and Market Access at Dubin, Ireland-based Mainstay Medical Holdings, has over 20 years in multiple leadership roles. His experience ranges from field sales leadership to leading teams at Medtronic and Senseonics that focused on managed markets and health economics. At Senseonics, Moebus led commercial and Medicare coverage and payment strategy and execution for the first implantable continuous glucose monitor in the U.S.
Clearly excited about Mainstay’s product, Chip Moebus told OTW, “My focus is to make sure patients have access to this incredible therapy. Expanding market access for ReActiv8 will play an essential role in successful commercialization, and I look forward to the progress that we will continue to make towards this goal.”
Mainstay Medical is laser-focused on one of the greatest challenges in musculoskeletal health—lower back pain. Its product, ReActiv8, is a tiny implantable device that stimulates the nerves that activate the stabilizing muscles of the lower back. Specifically, says Mainstay, “ReActiv8 provides bilateral electrical stimulation of the L2 medial branch of the dorsal ramus nerve as it crosses the transverse process at L3.”
Using a handheld wireless remote control, patients engage in ReActiv8 sessions twice a day for approximagely 30 minutes. According to the company, with continued use, ReActiv8 sessions may help the brain and body get better at controlling the muscles in between sessions.
And Jason Hannon’s thoughts on Chip Moebus?
“Chip possesses broad expertise in the reimbursement sector of the medical device industry and his skills are already having a positive impact on paving the way for patient access to ReActiv8.”
